NEUP: financial statements from SEC — TradeAlmanac

NEUP

Neuphoria Therapeutics Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024
Revenue	—	—	—	15m	662,715	—
Research and development	—	697,723	4m	2m	2m	2m
Selling, general and administrative	2m	2m	2m	1m	3m	2m
Operating expenses	1m	4m	6m	3m	4m	4m
Operating income	−1m	−4m	−6m	12m	−4m	−4m
Pre-tax income	−539,856	2m	−10m	11m	−2m	−936,974
Income tax	−34,793	−34,794	−34,793	−81,186	11,609	−132,187
Net income	−505,063	2m	−10m	11m	−2m	−804,787
Earnings per share	−0.09	0.41	−4.41	6.55	−1.23	−0.62
Earnings per share, diluted	−0.09	−0.77	−4.41	6.55	−1.79	−0.62
Weighted average shares	5m	5m	2m	2m	2m	1m
Weighted average shares, diluted	5m	5m	2m	2m	2m	1m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Jan 31, 2025	Dec 31, 2024	Sep 30, 2024
Cash and equivalents	19m	22m	14m	14m	17m	—	4m	8m
Receivables	2m	1m	1,758

Cash flow

Metric	Sep 30, 2025	Sep 30, 2024
Operating cash flow	−4m	−4m
Depreciation and amortisation	165,792	165,713
Share-based compensation	111,277	26,736
Financing cash flow	3m	−227,338

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)